Cosentyx

— THERAPEUTIC DISORDERS TREATED —
  • Arthritis/rheumatic disorders
  • Psoriasis

Cosentyx Generic Name & Formulations

General Description

Secukinumab 75mg/0.5mL, 150mg/mL; soln for SC inj; 150mg/vial; lyophilized pwd for SC inj after reconstitution; preservative-free.

Pharmacological Class

Interleukin-17A antagonist.

How Supplied

Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (150mg)—1, 2; (75mg)—1; Single-dose vial—1

Generic Availability

NO

Cosentyx Indications

Indications

Active psoriatic arthritis (PsA) in patients aged ≥2yrs. Active enthesitis-related arthritis (ERA) in patients aged ≥4yrs. Active ankylosing spondylitis (AS) in adults. Active non-radiographic axial spondyloarthritis (nraxSpA) in adults with objective signs of inflammation.

Cosentyx Dosage and Administration

Adult

Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: PsA with coexistent plaque psoriasis: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. Other PsA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if PsA continues. Cosentyx may be administered with or without MTX. AS (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if AS continues. nraxSpA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks.

Children

AS or nraxSpA (<18yrs): not established. PsA (<2yrs or <15kg) or ERA (<4yrs or <15kg): not established. PsA (≥2yrs): ≥15–<50kg: 75mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Cosentyx may be administered with or without MTX. ERA (≥4yrs): ≥15–<50kg: 75mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.

Cosentyx Contraindications

Not Applicable

Cosentyx Boxed Warnings

Not Applicable

Cosentyx Warnings/Precautions

Warnings/Precautions

May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.

Cosentyx Pharmacokinetics

See Literature

Cosentyx Interactions

Interactions

Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.

Cosentyx Adverse Reactions

Adverse Reactions

Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.

Cosentyx Clinical Trials

See Literature

Cosentyx Note

Not Applicable

Cosentyx Patient Counseling

See Literature

Cosentyx Generic Name & Formulations

General Description

Secukinumab 75mg/0.5mL, 150mg/mL; soln for SC inj; 150mg/vial; lyophilized pwd for SC inj after reconstitution; preservative-free.

Pharmacological Class

Interleukin-17A antagonist.

How Supplied

Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (150mg)—1, 2; (75mg)—1; Single-dose vial—1

Generic Availability

NO

Cosentyx Indications

Indications

Moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.

Cosentyx Dosage and Administration

Adult

Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. For some patients, 150mg dose may be acceptable.

Children

<6yrs: not established. Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). Give by SC inj at Weeks 0, 1, 2, 3, and 4 then every 4 weeks thereafter. ≥6yrs (<50kg): 75mg; (≥50kg): 150mg.

Cosentyx Contraindications

Not Applicable

Cosentyx Boxed Warnings

Not Applicable

Cosentyx Warnings/Precautions

Warnings/Precautions

May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.

Cosentyx Pharmacokinetics

See Literature

Cosentyx Interactions

Interactions

Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.

Cosentyx Adverse Reactions

Adverse Reactions

Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.

Cosentyx Clinical Trials

See Literature

Cosentyx Note

Not Applicable

Cosentyx Patient Counseling

See Literature

Images